Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Tumor necrosis factor inhibitors

7 evidence topics · 5 sources

Pivotal trial efficacy of infliximab, adalimumab, and golimumab: ACG 2025 guideline
Efficacy tiers by prior advanced-therapy exposure: AGA 2024 living guideline

“In patients who are naïve to advanced therapies, the AGA suggests using a higher efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab) or an intermediate efficacy medication (golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab), rather than a lower efficacy medication (adalimumab).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In patients who have previously been exposed to one or more advanced therapies, particularly tumor necrosis factor-α (TNF) antagonists, the AGA suggests using a higher efficacy medication (tofacitinib, upadacitinib, ustekinumab) or an intermediate efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a lower efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Infliximab has a possibly important benefit in achieving remission compared with adalimumab, mirikizumab, tofacitinib, and filgotinib with a low certainty of evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Notably, there was no RCT for infliximab or golimumab in patients with prior exposure to biologics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote